NICEx

Market Access

NICE’s health inequalities modular update: Commentary on NIC...

NICE’s modular update on health inequalities, consulted on in January and finalised in May, has now been incorporated into its manual.1 A total of 26 individuals and organi

News

Scientist working in a laboratory with apparatus

Charities call for shake-up in UK rare disease R&D

LifeArc and Genetics Alliance UK have issued a call to the government to remove obstacles impeding R&D into rare diseases.

News

NICE relents on Takeda colorectal cancer drug Fruzaqla

Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.

News

NHS starts first national rollout of Blenrep for myeloma

England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.

Market Access

Is money the only metric that really matters in UK’s VPAG? I...

The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.

R&D

NICE’s health inequalities modular update: Commentary on NIC...

Charities call for shake-up in UK rare disease R&D

NICE relents on Takeda colorectal cancer drug Fruzaqla

NHS starts first national rollout of Blenrep for myeloma

Is money the only metric that really matters in UK’s VPAG? I...

Where innovation meets collaboration: Live from Manchester’s...

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

NICEx

Editor's Picks